Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

North - Hmm, so this generic patent irritation

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Mocha Loca Member Profile
 
Followed By 5
Posts 110
Boards Moderated 0
Alias Born 09/27/19
160x600 placeholder
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 2/20/2020 6:00:10 AM
Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020 GlobeNewswire Inc. - 2/19/2020 4:15:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:25:35 PM
Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval GlobeNewswire Inc. - 2/6/2020 9:26:23 PM
Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire Inc. - 1/13/2020 6:00:10 AM
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire Inc. - 1/7/2020 6:00:10 AM
Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/6/2020 6:00:10 AM
VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire Inc. - 1/2/2020 6:00:10 AM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk PR Newswire (US) - 12/13/2019 6:14:00 PM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk GlobeNewswire Inc. - 12/13/2019 4:49:07 PM
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) f... GlobeNewswire Inc. - 12/2/2019 6:00:10 AM
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions GlobeNewswire Inc. - 11/18/2019 5:30:00 PM
Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award GlobeNewswire Inc. - 11/18/2019 12:15:12 PM
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsule... GlobeNewswire Inc. - 11/14/2019 5:34:37 PM
Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking N... GlobeNewswire Inc. - 11/14/2019 6:59:25 AM
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthca... GlobeNewswire Inc. - 11/11/2019 1:19:57 PM
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular R... GlobeNewswire Inc. - 11/11/2019 6:30:48 AM
Amarin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/11/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 5:29:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 6:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 6:31:38 AM
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/5/2019 5:00:00 AM
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 11/4/2019 6:00:00 AM
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019 GlobeNewswire Inc. - 10/24/2019 4:30:05 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
Mocha Loca   Thursday, 12/05/19 02:10:13 AM
Re: north40000 post# 231658
Post # of 247599 
North - Hmm, so this generic patent irritation can go on for as long as there is exclusivity? Hmm. That makes sense. I'm assuming though as time goes by, suing becomes less and less attractive due to time constraints and the first mover rights of prior filers. So I'm assuming the fact it can happen again regardless wouldn't impact any decisions on how to handle the current suit, or no?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist